Inhibition Control of Children and Adolescents With ADHD

Attention Deficit Hyperactivity Disorder Clinical Trial

Official title:

Inhibition Control of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01677819
• Other study ID #: 201109027RD
• Status: Completed
• Phase: N/A
• First received: August 30, 2012
• Last updated: August 30, 2012
• Start date: November 2011
• Est. completion date: March 2012

Study information

• Verified date: August 2012
• Source: National Taiwan University Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Taiwan: Department of Health
• Study type: Observational

Clinical Trial Summary

The objectives of this study are to investigate:

1. the effect of methylphenidate on attention;

2. the relations between methylphenidate and inhibition control and working memory;

3. the relations between inhibition control and verbal attention and working memory;

4. the effect of methylphenidate on the changes of neuropsychological functioning and blood pressure.

Description:

Attention deficit hyperactivity disorder (ADHD), characterized by inattention, hyperactivity and impulsivity, is an early onset, highly heritable, clinically heterogeneous, long-term impairing disorder with tremendous impact on individuals, families, and societies. It affects 5-10% of school-aged children worldwide (7.5% in Taiwan). Methylphenidate, a stimulant, is effective in treating these patients. Studies in Taiwan show no effect of methylphenidate on blood pressure. There are evidences show that the change of blood pressure was associated with inhibition of impulsive behaviors. Stop Signal Task(SST) is used to assess the improve of inhibition control after methylphenidate response. By using repeated outcome measurements, we anticipate that this study will evaluate the improvement of neuropsychological performances after medication and determinie the association between medication response and neuropsychological functions and vital signs in a Taiwanese sample.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: March 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 10 Years to 18 Years

Eligibility

Inclusion Criteria:

The inclusion criteria for the subjects are (1)that subjects have a clinical diagnosis of ADHD defined by the DSM-IV which was made by a full-time board-certificated child psychiatrist; (2)their ages range from 10 to 18 when we conduct the study; (3)their IQ greater than 80; and (4)they are under treatment of methylphenidate.

Exclusion Criteria:

The subjects will be excluded from the study if they currently meet criteria or have a history of the following condition as defined by DSM-IV: Schizophrenia, Schizoaffective Disorder, Organic Psychosis, or Pervasive Developmental Disorder.

Study Design

N/A

Related Conditions & MeSH terms

• Attention Deficit Disorder with Hyperactivity
• Attention Deficit Hyperactivity Disorder
• Hyperkinesis

Locations

Country	Name	City	State
Taiwan	National Taiwan Univeristy Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan,